{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:28:40Z","timestamp":1793179720680,"version":"4.5.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"12","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Activated phosphoinositide 3-kinase delta (PI3K\u03b4) syndrome (APDS) is an inborn error of immunity that manifests as immune deficiency and dysregulation; symptoms include frequent infections and lymphoproliferation. In our dose-finding and phase 3 placebo-controlled trials, treatment with the selective PI3K\u03b4 inhibitor leniolisib reduced lymphoproliferation and normalized lymphocyte subsets. Here, we present 6 years of follow-up from the 6 adult patients in the original dose-finding trial receiving leniolisib. We used data from the ongoing open-label extension study, which was supplemented at later time points by investigators, including health-related quality of life (HRQoL) assessed through a clinician-reported questionnaire. We observed improvements in HRQoL: 5 of 6 patients experienced an increase in physical capabilities and socialization, and a decrease in prescribed medications. Immune subsets improved in all patients: mean transitional B-cell levels decreased from 38.17% to 2.47% and the CD4:CD8 T-cell ratio normalized to 1.11. Manifestations seen before and within the first year of leniolisib exposure, such as infections and gastrointestinal conditions, attenuated after year 2, with few new conditions emerging out to year 6. Thrombocytopenia or lymphopenia remained present in half of patients at year 6. Of 83 adverse events through year 5, 90.36% were grade 1; none were grade 4\/5 nor deemed leniolisib related. Collectively, we saw an enhancement in HRQoL as well as durable changes in lymphocyte subsets and clinical manifestations, further supporting the use of leniolisib as a long-term therapeutic option for the treatment of APDS. This trial was registered at www.ClinicalTrials.gov as #NCT02859727.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011000","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T18:56:06Z","timestamp":1712688966000},"page":"3092-3108","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Long-term treatment with selective PI3K\u03b4 inhibitor leniolisib in adults with activated PI3K\u03b4 syndrome"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7881-6902","authenticated-orcid":false,"given":"V. Koneti","family":"Rao","sequence":"first","affiliation":[{"name":"1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Kulm","sequence":"additional","affiliation":[{"name":"2Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Grossman","sequence":"additional","affiliation":[{"name":"3Alberta Health Services, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Children\u2019s Hospital of Orange County, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hey","family":"Chong","sequence":"additional","affiliation":[{"name":"5Division of Allergy and Immunology, University of Pittsburgh Medical Center Children\u2019s Hospital of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Bradt","sequence":"additional","affiliation":[{"name":"6Pharming Healthcare Inc, Warren, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Webster","sequence":"additional","affiliation":[{"name":"1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7730-2304","authenticated-orcid":false,"given":"Anna","family":"\u0160ediv\u00e1","sequence":"additional","affiliation":[{"name":"7Department of Immunology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgil A.","family":"Dalm","sequence":"additional","affiliation":[{"name":"8Division of Allergy and Clinical Immunology and Department of Immunology, Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulbu","family":"Uzel","sequence":"additional","affiliation":[{"name":"1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"issue":"6160","key":"2024062414554685200_bib1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage","volume":"342","author":"Angulo","year":"2013","journal-title":"Science"},{"issue":"1","key":"2024062414554685200_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol"},{"issue":"13","key":"2024062414554685200_bib3","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1084\/jem.20141759","article-title":"Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K","volume":"211","author":"Lucas","year":"2014","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"2024062414554685200_bib4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"2024062414554685200_bib5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","article-title":"Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: a cohort study","volume":"138","author":"Elkaim","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"2024062414554685200_bib6","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.jaci.2019.03.017","article-title":"PI3K pathway defects leading to immunodeficiency and immune dysregulation","volume":"143","author":"Nunes-Santos","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"2024062414554685200_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.02043","article-title":"The treatment of activated PI3Kdelta syndrome","volume":"9","author":"Coulter","year":"2018","journal-title":"Front Immunol"},{"key":"2024062414554685200_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.00543","article-title":"Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase delta syndrome: the European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase delta Syndrome Registry","volume":"9","author":"Maccari","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"2024062414554685200_bib9","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1016\/j.jaip.2021.07.044","article-title":"Clinical manifestations and outcomes of activated phosphoinositide 3-kinase delta syndrome from the USIDNET Cohort","volume":"9","author":"Oh","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"9","key":"2024062414554685200_bib10","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood.2019002072","article-title":"Increased activation of PI3 kinase-delta predisposes to B-cell lymphoma","volume":"135","author":"Durandy","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2024062414554685200_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jaci.2018.04.030","article-title":"Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity","volume":"143","author":"Edwards","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"2024062414554685200_bib12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10875-015-0196-7","article-title":"Perceived health in patients with primary immune deficiency","volume":"35","author":"Seeborg","year":"2015","journal-title":"J\u00a0Clin Immunol"},{"issue":"6","key":"2024062414554685200_bib13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1037\/spq0000311","article-title":"School students with chronic illness have unmet academic, social, and emotional school needs","volume":"34","author":"Lum","year":"2019","journal-title":"Sch Psychol"},{"issue":"2","key":"2024062414554685200_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/002221949302600204","article-title":"School reentry for the child with chronic illness","volume":"26","author":"Sexson","year":"1993","journal-title":"J\u00a0Learn Disabil"},{"issue":"3","key":"2024062414554685200_bib15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/10349120120073412","article-title":"Issues in the education of students with chronic illness","volume":"48","author":"Shiu","year":"2001","journal-title":"Int J Disabil Dev Educ"},{"issue":"3","key":"2024062414554685200_bib16","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.4081\/hpr.2013.932","article-title":"Quality of life in chronic disease patients","volume":"1","author":"Megari","year":"2013","journal-title":"Health Psychol Res"},{"issue":"9","key":"2024062414554685200_bib17","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ajim.22439","article-title":"Multiple chronic conditions and labor force outcomes: a population study of U.S. adults","volume":"58","author":"Ward","year":"2015","journal-title":"Am J Ind Med"},{"key":"2024062414554685200_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2022.108931","article-title":"Health-related quality of life in primary immunodeficiencies: impact of delayed diagnosis and treatment burden","volume":"236","author":"Anderson","year":"2022","journal-title":"Clin Immunol"},{"key":"2024062414554685200_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13223-015-0092-y","article-title":"Health-related quality of life in patients with primary immunodeficiency disease","volume":"11","author":"Jiang","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"21","key":"2024062414554685200_bib20","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \"activated PI3Kdelta syndrome\"-targeted therapy with the PI3Kdelta inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2024062414554685200_bib21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2022018546","article-title":"A\u00a0randomized, placebo-controlled phase 3 trial of the PI3Kdelta inhibitor leniolisib for activated PI3Kdelta syndrome","volume":"141","author":"Rao","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2024062414554685200_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaci.2023.09.032","article-title":"Interim analysis: open-label extension study of leniolisib for patients with APDS","volume":"153","author":"Rao","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"2024062414554685200_bib23","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.jaci.2016.11.029","article-title":"Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16)","volume":"139","author":"Ballow","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"2024062414554685200_bib24","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaip.2016.07.012","article-title":"Development and initial validation of a questionnaire to measure health-related quality of life of adults with common variable immune deficiency: the CVID_QoL Questionnaire","volume":"4","author":"Quinti","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"2024062414554685200_bib25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s10875-016-0279-0","article-title":"Health-related quality of life and health resource utilization in patients with primary immunodeficiency disease prior to and following 12\u00a0months of immunoglobulin G treatment","volume":"36","author":"Routes","year":"2016","journal-title":"J\u00a0Clin Immunol"},{"key":"2024062414554685200_bib44","author":"Maruish","year":"2011"},{"issue":"5","key":"2024062414554685200_bib45","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024062414554685200_bib46","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.acra.2013.01.011","article-title":"Assessing splenomegaly: automated volumetric analysis of the spleen","volume":"20","author":"Linguraru","year":"2013","journal-title":"Acad Radiol"},{"issue":"2","key":"2024062414554685200_bib42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2249.2010.04206.x","article-title":"Reference values for B cell subpopulations from infancy to adulthood","volume":"162","author":"Morbach","year":"2010","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2024062414554685200_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.clim.2009.05.020","article-title":"Refined characterization and reference values of the pediatric T- and B-cell compartments","volume":"133","author":"van Gent","year":"2009","journal-title":"Clin Immunol"},{"key":"2024062414554685200_bib34","unstructured":"Laboratory Corporation of America\n          . Immunoglobulin G, Quantitative. Updated 2021. Accessed 22 February 2023. https:\/\/www.labcorp.com\/tests\/001776\/immunoglobulin-g-quantitative."},{"key":"2024062414554685200_bib35","unstructured":"Laboratory Corporation of America\n          . Immunoglobulin A, Quantitative. Updated 2021. Accessed 22 February 2023. https:\/\/www.labcorp.com\/tests\/001784\/immunoglobulin-a-quantitative."},{"key":"2024062414554685200_bib36","unstructured":"Laboratory Corporation of America\n          . Immunoglobulin M, Quantitative. Updated 2021. Accessed 22 February 2023. https:\/\/www.labcorp.com\/tests\/001792\/immunoglobulin-m-quantitative."},{"key":"2024062414554685200_bib37","unstructured":"Laboratory Corporation of America\n          . Immunoglobulin E, Total. Updated 2021. Accessed 22 February 2023. https:\/\/www.labcorp.com\/tests\/002170\/immunoglobulin-e-total."},{"issue":"1","key":"2024062414554685200_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/JCM.41.1.187-191.2003","article-title":"Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients","volume":"41","author":"Li","year":"2003","journal-title":"J\u00a0Clin Microbiol"},{"issue":"24","key":"2024062414554685200_bib27","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"2024062414554685200_bib38","unstructured":"Laboratory Corporation of America\n          . Immunoglobulin G, Subclass 1. Updated 2021. Accessed 22 February 2023. https:\/\/www.labcorp.com\/tests\/160507\/immunoglobulin-g-subclass-1."},{"key":"2024062414554685200_bib39","unstructured":"Laboratory Corporation of America\n          . Immunoglobulin G, Subclass 2. Updated 2021. Accessed 22 February 2023. https:\/\/www.labcorp.com\/tests\/160515\/immunoglobulin-g-subclass-2."},{"key":"2024062414554685200_bib40","unstructured":"Laboratory Corporation of America\n          . Immunoglobulin G, Subclass 3. Updated 2021. Accessed 22 February 2023. https:\/\/www.labcorp.com\/tests\/160523\/immunoglobulin-g-subclass-3."},{"key":"2024062414554685200_bib41","unstructured":"Laboratory Corporation of America\n          . Immunoglobulin G, Subclass 4. Updated 2021. Accessed 22 February 2023. https:\/\/www.labcorp.com\/tests\/160531\/immunoglobulin-g-subclass-4."},{"issue":"4","key":"2024062414554685200_bib28","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"2024062414554685200_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/PPA.S58040","article-title":"Health-related quality of life, anxiety, and depressive symptoms in children with primary immunodeficiencies","volume":"8","author":"Kuburovic","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"2024062414554685200_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00605","article-title":"Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies","volume":"5","author":"Tabolli","year":"2014","journal-title":"Front Immunol"},{"issue":"14","key":"2024062414554685200_bib31","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood.2022015506","article-title":"Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study","volume":"140","author":"Albert","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024062414554685200_bib32","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaci.2021.04.036","article-title":"International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome","volume":"149","author":"Dimitrova","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9","key":"2024062414554685200_bib33","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1021\/acsmedchemlett.7b00293","article-title":"Discovery of CDZ173 (leniolisib), representing a structurally novel class of PI3K delta-selective inhibitors","volume":"8","author":"Hoegenauer","year":"2017","journal-title":"ACS Med Chem Lett"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/12\/3092\/2232202\/blooda_adv-2023-011000-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/12\/3092\/2232202\/blooda_adv-2023-011000-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T14:56:33Z","timestamp":1719240993000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/12\/3092\/515673\/Long-term-treatment-with-selective-PI3K-inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011000","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]}}}